Cas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (BSA and Azide Free)#10612,Cell Signaling Technology (CST),10612

Cas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (BSA and Azide Free) recognizes transfected levels of total Cas9 protein.

Host

Mouse

Reactivity

All Species Expected

Platform ID

BAB405006177

Cell Signaling Technology (CST)

Headquarters

3 Trask Lane Danvers, MA 01923

Contact

Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355

Product Specifications
Scientific Background
Synonyms

Specifications

NameCas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (BSA and Azide Free)#10612
Cat. No.10612
Accession NumberQ99ZW2, 901176
Gene ID (Entrez)901176
HostMouse
SensitivityTransfected Only
ReactivityAll Species Expected
Molecular Weight160
ImmunogenIgG1
FormulationThis product is the carrier free version of product #14697. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol.This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN, or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, pleasecontact us. Optimal dilutions/concentrations should be determined by the end user.BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity.
StorageStore at –20°C.This product will freeze at –20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.
Regulatory StatusResearch Use Only

Scientific Background

The CRISPR associated protein 9 (Cas9) is an RNA-guided DNA nuclease and part of theStreptococcus pyogenesCRISPR antiviral immunity system that provides adaptive immunity against extrachromosomal genetic material (1). The CRISPR antiviral mechanism of action involves three steps: (i), acquisition of foreign DNA by host bacterium; (ii), synthesis and maturation of CRISPR RNA (crRNA) followed by the formation of RNA-Cas nuclease protein complexes; and (iii), target interference through recognition of foreign DNA by the complex and its cleavage by Cas nuclease activity (2). The type II CRISPR/Cas antiviral immunity system provides a powerful tool for precise genome editing and has potential for specific gene regulation and therapeutic applications (3). The Cas9 protein and a guide RNA consisting of a fusion between a crRNA and a trans-activating crRNA (tracrRNA) must be introduced or expressed in a cell. A 20-nucleotide sequence at the 5' end of the guide RNA directs Cas9 to a specific DNA target site. As a result, Cas9 can be "programmed" to cut various DNA sites bothin vitroand in cells and organisms. CRISPR/Cas9 genome editing tools have been used in many organisms, including mouse and human cells (4,5). Research studies demonstrate that CRISPR can be used to generate mutant alleles or reporter genes in rodents and primate embryonic stem cells (6-8).Horvath, P. and Barrangou, R. (2010)Science327, 167-70.Wiedenheft, B. et al. (2012)Nature482, 331-8.Singh, P. et al. (2015)Genetics199, 1-15.Cong, L. et al. (2013)Science339, 819-23.Mali, P. et al. (2013)Science339, 823-6.Li, D. et al. (2013)Nat Biotechnol31, 681-3.Shen, B. et al. (2013)Cell Res23, 720-3.Niu, Y. et al. (2014)Cell156, 836-43.Alternate Namescas9; CRISPR-associated endonuclease Cas9/Csn1; csn1

Synonyms

cas9; CRISPR-associated endonuclease Cas9/Csn1; csn1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.